Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4081 AL 4095

Mechanisms of vascular disease in dementia: what does industry want to know?

Wren PB, Hill D, Lockhart A.

Clin Sci (Lond). 2017 May 1;131(9):799-802. doi: 10.1042/CS20160724.

Neuroinflammation in Alzheimer's Disease: The Preventive and Therapeutic Potential of Polyphenolic Nutraceuticals

Sawikr Y, Yarla NS, Peluso I, Kamal MA, Aliev G, Bishayee A.

Adv Protein Chem Struct Biol. 2017;108:33-57. doi: 10.1016/bs.apcsb.2017.02.001. Epub 2017 Mar 22.

Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts

Scheltens NME, Tijms BM, Koene T, Barkhof F, Teunissen CE, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Cohn-Sheehy BI, Rabinovici GD, Miller BL, Kramer JH, Scheltens P, van der Flier WM; German Dementia Competence Network; University of California San Francisco Memory and Aging Center; Amsterdam Dementia Cohort.

Alzheimers Dement. 2017 Nov;13(11):1226-1236. doi: 10.1016/j.jalz.2017.03.002. Epub 2017 Apr 17.

Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease

Zhao N, Liu CC, Qiao W, Bu G.

Biol Psychiatry. 2018 Feb 15;83(4):347-357. doi: 10.1016/j.biopsych.2017.03.003. Epub 2017 Mar 14.

Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer's Disease

Shevtsova EF, Vinogradova DV, Neganova ME, Avila-Rodriguez M, Ashraf GM, Barreto GE, Bachurin SO, Aliev G.

CNS Neurol Disord Drug Targets. 2017;16(6):677-685. doi: 10.2174/1871527316666170424114444.

Nanoparticles as potential clinical therapeutic agents in Alzheimer's disease: focus on selenium nanoparticles

Nazıroğlu M, Muhamad S, Pecze L.

Expert Rev Clin Pharmacol. 2017 Jul;10(7):773-782. doi: 10.1080/17512433.2017.1324781. Epub 2017 May 16.

Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer's Disease

Xie J, Wang H, Lin T, Bi B.

Biomed Res Int. 2017;2017:2986460. doi: 10.1155/2017/2986460. Epub 2017 Apr 3.

Pathophysiology in the comorbidity of Bipolar Disorder and Alzheimer's Disease: pharmacological and stem cell approaches

Corrêa-Velloso JC, Gonçalves MC, Naaldijk Y, Oliveira-Giacomelli Á, Pillat MM, Ulrich H.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt A):34-53. doi: 10.1016/j.pnpbp.2017.04.033. Epub 2017 May 3.

The Exceptional Vulnerability of Humans to Alzheimer's Disease

Walker LC, Jucker M.

Trends Mol Med. 2017 Jun;23(6):534-545. doi: 10.1016/j.molmed.2017.04.001. Epub 2017 May 5.

Dysregulated Metabolism of the Amyloid-β Protein and Therapeutic Approaches in Alzheimer Disease

Kikuchi K, Kidana K, Tatebe T, Tomita T.

J Cell Biochem. 2017 Dec;118(12):4183-4190. doi: 10.1002/jcb.26129. Epub 2017 Jun 9.

Emerging amyloid and tau targeting treatments for Alzheimer's disease

Khan A, Corbett A, Ballard C.

Expert Rev Neurother. 2017 Jul;17(7):697-711. doi: 10.1080/14737175.2017.1326819. Epub 2017 May 19.

Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets

Khan A, Corbett A, Ballard C.

Expert Rev Neurother. 2017 Jul;17(7):683-695. doi: 10.1080/14737175.2017.1326818. Epub 2017 May 18.

Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease

Knez D, Sova M, Košak U, Gobec S.

Future Med Chem. 2017 May;9(8):811-832. doi: 10.4155/fmc-2017-0036. Epub 2017 May 15.

Modulating 5-HT(4) and 5-HT(6) receptors in Alzheimer's disease treatment

Lalut J, Karila D, Dallemagne P, Rochais C.

Future Med Chem. 2017 May;9(8):781-795. doi: 10.4155/fmc-2017-0031. Epub 2017 May 15.

Cyclin dependent kinase 5: A novel avenue for Alzheimer's disease

Bhounsule AS, Bhatt LK, Prabhavalkar KS, Oza M.

Brain Res Bull. 2017 Jun;132:28-38. doi: 10.1016/j.brainresbull.2017.05.006. Epub 2017 May 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias